Meda acquires Women’s Health products in the U.S.
· Meda acquires a portfolio of pharmaceutical products within Women’s Health from Jazz Pharmaceuticals · Meda increases the presence in an area where the company is active · An experienced sales force of about 60 reps joins Meda · Sales level around 200 MSEK and with good profitability · Purchase price 95 MUSD, corresponding to 3 times sales Meda has signed an agreement with the U.S. company Jazz Pharmaceuticals to acquire a portfolio of 6 pharmaceutical products focused on Women’s Health. The largest and most important product is Elestrin, a patented